Intellia Therapeutics NTLA has made meaningful progress with the development of its in vivo programs. The company is currently advancing two late-stage in vivo candidates — lonvo-z (or, NTLA-2002) for ...

As developers of gene editing therapies and other genetic medicines get set to report third quarter earnings in coming days, analysts and especially investors will keep their eyes on whether the ...

From the 2010s to the present, the existing technologies in the clinic and operating room have been improved with the goals ...

Despite setbacks and funding cuts — and a quieting of the hype blaring its arrival — multiple CRISPR-based trials are ...

Baby KJ's medical team intend to ask the FDA to start a clinical trial that would be open to patients with seven different ...

Since 2019, MIT researchers have published a new concept called prime editing, which is more precise than regular CRISPR-Cas9 gene editing. As a result, it has fewer off-target effects and less chance ...

Crispr Therapeutics AG ( ($CRSP) ) has issued an update. On October 15, 2025, CRISPR Therapeutics AG announced the filing of a prospectus ...

The influenza A virus (IAV) has been the cause of six major flu pandemics, responsible for 50 to 100 million deaths globally.

Kansas State University researchers and the state’s farmers are putting their collective support behind a project to reduce ...

Cathie Wood, CEO of Ark Invest, believes healthcare is the most profound application of AI and Wall Street is overlooking its ...

Attempting to cash in on what's likely to be a relatively short-lived mania isn't a good idea for most investors most of the ...

Scientists are researching ways to genetically modify plants and animals to be more resistant to threats like climate change.